Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2026-03-31

Clinical Trial Update: Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating add-on Rademikibart for acute exacerbations of chronic obstructive pulmonary disease is currently recruiting (NCT06940154).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Rademikibart

Snippet

Sponsor: Connect Biopharm LLC | Conditions: COPD Acute Exacerbation | Phase 2 | Status: RECRUITING